Lv6
2790 积分 2023-07-17 加入
The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062
6个月前
已完结
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
6个月前
已完结
Sacituzumab govitecan: past, present and future of a new antibody–drug conjugate and future horizon
6个月前
已完结
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)
7个月前
已完结
HER3-addicted tumors: how biotechs are closing in
7个月前
已完结
An Overview of CDK Enzyme Inhibitors in Cancer Therapy
1年前
已完结
CDK inhibitors from past to present: A new wave of cancer therapy
1年前
已完结
Small-molecule degraders of cyclin-dependent kinase protein: a review
1年前
已完结
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
1年前
已完结
Applications of Bioisosteres in the Design of Biologically Active Compounds
1年前
已完结
皖公网安备34019202002308
